|
1. Biologie
|
|
|
|
|
2.11 Etiologie - Alimentation
|
|
|
|
3.1 Tabac
|
|
|
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
5.9.5 AACR - T-cell immunothérapies
|
|
|
|
6.1 Observation
|
|
|
|
6.10 Politiques
|
|
|
Biden time [Nature News & Commrnt]
|
|
|
|
|
|
The
US National Cancer Institute has made it clear that it wants to hear
recommendations from the community, and has a website dedicated to
stimulating participation. This participation need not be restricted to
US researchers: international scientists and clinicians should submit
recommendations, too.
|
|
|
|
|
|
|
6.11 Patients
|
|
|
|
6.9 Controverses
|
|
|
|
5 Tips For Avoiding P-Value Potholes [Absolutely Maybe]
|
|
|
|
|
|
The
“bright line” of p-values at 0.05 is taught because the scientific
community and journals use it so much. And they use it so much because
that’s what they’re taught. The result is a bumpy ride in the
literature. Here’s my choice of the top 5 things to keep in mind to
avoid p-value potholes.
|
|
|
|
|
|